Advertisement

Today's Headlines

Safety Profile of Ixazomib in Japanese Patients with Relapsed/Refractory MM

A study published in Internal Medicine evaluated the safety profile of ixazomib in a cohort of Japanese patients with relapsed/refractory multiple myeloma (MM). Ixazomib is a proteasome inhibitor improved in both the US and Japan in combination with other therapies...
- Advertisement -
- Advertisement -

Expert Interviews

00:03:24

Optimal Treatment Sequencing: Trial Results

Dr. Usmani: When speaking about anti-CD38 based combination triplets, we have several options in the early relapse, one to three prior lines of treatment. And,...
00:06:21

Recent Clinical Data

Dr. Usmani: Amrita, you actually presented data at recently concluded ASCO meeting as well. So, the commentary there is for CAT T-cells, you have to...
00:03:47

BCMA – Targeting Therapies

Dr. Usmani: Hello, everyone. We are going to start our second roundtable, which will focus on the latest news and clinical development and impact for...
00:04:11

COVID-19 in the Multiple Myeloma Patient

Saad Z. Usmani, MD, FA: We have had to adjust to the realities of the COVID-19 pandemic. And I think Sydney, you were based in...
00:04:37

Expanding Access to Multiple Myeloma Clinical Trials, with Dr. Sborov

Multiple Myeloma Today spoke with Douglas Sborov, MD, Director of the Multiple Myeloma Program, Huntsman Cancer Institute at the University of Utah, about recent...
00:05:49

Multiple Myeloma Care During the Pandemic, with Dr. Sborov

Multiple Myeloma Today sat down with Douglas Sborov, MD, Director of the Multiple Myeloma Program, Huntsman Cancer Institute at the University of Utah, to...

Journal Abstracts